Clinical Utility of GST and CEA in Gastrointestinal Cancer
Journal Title: International Journal of Innovative Research in Medical Science - Year 2017, Vol 2, Issue 7
Abstract
Purpose: - To analyze the level of serum Glutathione-S-Transferase (GST) and Carcinoembryonic antigen (CEA) before and after different Cycles Of chemotherapy in GI carcinoma patients. Methods: - For the study comprising total 58 cases suffering from GI carcinoma stage I, stage II stage III and Stage IV (before and after different cycle of chemotherapy) were selected. All patients were clinically and histologically diagnosed. A total of 42 age and sex matched healthy subjects taken as control. The circulating levels of GST and CEA activity were assayed in the in the serum of control group and in patients with GI carcinoma. Results: - Serum level of GST and CEA were highly significant in GI carcinoma patients as compared to control group (p<0.001). After first cycle of chemotherapy (stage II) the activity of GST and CEA were significantly higher than before chemotherapy (stage I). In stage III (after second cycle of chemotherapy) activity was significantly decreased than that of stage II and the activity of GST and CEA was significantly decreased in stage IV (after third cycle of chemotherapy) than stage III (after second cycle of chemotherapy). Conclusion:- On the basis of data from our study, it can be stated that serum GST measurement in plasma may be useful tumor marker in gastrointestinal carcinoma, its activity might helpful to predict the response of chemotherapy in advance stage of cancer. CEA is a tumor marker that is measured using a blood test.CEA tumor marker is one of the general type tumor markers. A multiply increased CEA levels in the blood indicate to the presence of a malignant disease in the body, but not to the organ in which the malignant change has occurred. High levels of CEA may indicate that cancer has spread; however, other medical conditions and some treatments, including certain types of chemotherapy, may raise CEA levels. CEA tests are one way doctors can find out whether the cancer has spread or returned. Cancer that has spread or returned can be treated successfully for many patients. CEA measurement is mainly used to identify recurrences after surgical resection and for staging.
Authors and Affiliations
Ranjit S. Ambad, Rajesh Bhanudas Rajekar, Nishikant Ingole
Keywords
Related Articles
- EP ID EP449381
- DOI -
- Views 84
- Downloads 0
A Sporadic Case of Darier Disease with Acrokeratosis Verruciformis like Lesions: Treated Effectively with Oral and Topical Retinoid
Darier disease (DD) is a type of autosomal dominant genodermatosis with calcium pump defect. We are reporting a case of Darier disease because of its rarity. A 24 year old man presented with multiple pruritic dark warty...
Tragal Cartilage Versus Polytetrafluoroethylene (TEFLON) Partial Ossicular Replacement Prosthesis (PORP): A Comparative Study of Outcomes of Ossiculoplasty
Reconstruction of the conductive mechanism of the middle ear is one of the most intriguing topics in middle ear surgery. An implant in middle ear should be safe, biocompatible, stable, easily insertable and capable of yi...
Bromatological Analysis from Medicinally Relevant Wild Edible Plant Parts
The wild edible plant parts such as tubers, rhizomes, corm, fruits, inflorescence, leaves, flowers, stems were consumed by rural peoples of Kolhapur district, Maharashtra, India. Ten wild edible plant species viz. Bauhin...
Serum Procalcitonin, Use of Antibiotics, and Patient Outcome
Objective: To evaluate the impact of serum procalcitonin (PCT) testing on use of antibiotics and patient outcome. Design: A retrospective chart review evaluation of the patients who had a serum procalcitonin test perform...
Study of Clinical Profile, Risk Factors, Pattern of Drug Resistance and Treatment Outcome in Previously Treated Patients of Pulmonary Tuberculosis
Introduction: Tuberculosis has been a scourge of mankind from times immemorial and still an important public health problem in India and other developing countries. An estimated 3.3% of new cases and 20% of previously tr...